Navigation Links
Qforma Unveils Managed Care Optimization Solution for Pharma Marketing Executives
Date:4/14/2008

iQMCO(TM) Helps Managed Market Teams Choose Best Plans for Their Brands

SANTA FE, N.M., April 14 /PRNewswire/ -- Qforma, an advanced analytics company, today announced the introduction of iQMCO(TM), the Managed Care Optimization model. This innovative new tool was developed to help pharmaceutical managed market executives create informed contracting and pull-through strategies. iQMCO(TM) utilizes advanced modeling techniques to pinpoint the payors who are most effective at implementing formulary decisions.

The iQMCO(TM) is an easy-to-use, real-time tool that integrates the product knowledge and strategic insights of a managed market team with robust methodologies. iQMCO(TM) quantitatively scores and ranks more than 2,100 payors based on modeling outcomes of both qualitative and quantitative data. This is accomplished by adjusting model attributes that are most important to the customer, revealing immediate rankings in just the click of a mouse.

"Managed market professionals expressed a need to make objective contracting decisions for their product portfolios," said Kelly D. Myers, CEO of Qforma. "We created iQMCO(TM) to provide quantitative insights which effectively prioritize the payors best positioned to deliver on specific goals. The results help them optimize rebate strategies."

Using iQMCO(TM), managed market teams run scenarios by adjusting model attributes based on a number of different qualitative and quantitative data categories of their choice. The model then quantifies a "score" for each payor and ranks its importance to a company's brand goals regionally or nationally.

About Qforma

Qforma is an advanced analytics and predictive modeling company specializing in solutions for the healthcare industry. Qforma leverages the talents of physicists, mathematicians and programmers, and has developed a unique approach to quantifying large data flows with the purpose of eliminating the inefficiencies of traditional sa
'/>"/>

SOURCE Qforma
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. CVS Caremark Charity Classic Golf Tournament Unveils 10th Anniversary Field
2. UHW Unveils Proposals for SEIU Convention
3. Advancing Interoperability - Nonin(R) Medical Unveils Worlds First Bluetooth(R)-Enabled, Wireless Fingertip Pulse Oximeter
4. AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM)
5. Registry unveils real-world data on novel excel stent
6. LA Career Coach Unveils LifeStage Methodology to Help Individuals Make Effective Work-Life Choices
7. Video: TI unveils industrys first family of complete analog front ends for superior ultrasound systems
8. Hazelden Publishing Unveils Valuable New Resource for Women Seeking Recovery From Addiction
9. Genetic research unveils common origins for distinct clinical diagnoses
10. D1 Spas Unveils Worlds First Underwater Gym at IHRSA 2008
11. VIDEO from Medialink and Philips: Philips Electronics Unveils First Imagination Light Canvas at the New Mercy Medical Center in Rogers AR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...on models are enhanced by taking into account risk...ity, according to research teams led by epidemiolo...ncer Center in two complementary papers appearing ...rch . , In the first study to focus on African-A...n increased exposure to certain risks. Based upon ...
(Date:9/4/2008)...wswire/ -- A groundbreaking program,dealing with t...atus of,men, their shorter life spans, unmet gende...ke place Wednesday, September 17 at White Plains,H... of the Westchester,medical and psychiatric societ... and Lionel Tiger, Ph.D., Dr. Legatto, an interna...
(Date:9/4/2008)...ivate Medicare Advantage (MA) plans will be paid a...ompared to what the same enrollee would have cost ...m, according to a new report from The Commonwealth... mandated by the Medicare Improvements for Patient...take effect beginning in 2010 had been fully in p...
(Date:9/4/2008)...ns may be shortchanging their golden years by tapp...University of Illinois expert who has studied the ... , More than three of every four Americans trim ...laiming benefits early, a choice many might forego...nd consequences, law professor Richard L. Kaplan s...
Breaking Medicine News(10 mins):Health News:Creating lung cancer risk models for specific populations refines prediction 2Health News:Creating lung cancer risk models for specific populations refines prediction 3Health News:Extra payments to Medicare Advantage plans to total $8.5 billion in 2008 2Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3
... levels of stress experienced by children may hamp...n suffering from post-traumatic// stress disorder ... memory and emotion had become smaller in size. C...stress and anxiety when their hippocampus is shrun...
...in, say researchers at the Stanford University Sch...spital. The researchers found that children with p...he stress hormone cortisol were likely to experien...n structure important in memory processing and emo...
...on for health professionals must include teaching ...//cancer about sex, cancer experts say. Sexuality... want to discuss with their doctor or member of th...rn of the Cancer Council Victoria, and Dr Annette ...
...hat a new technique safely and effectively removes...t risk for pulmonary embolism and disability. Th...n to have a positive impact on patients’ quality o...in and swelling, as well as greatly improving thei...
Other Medicine News:Health News:Child Brain Likely To Be Harmed By Stress 2Health News:Severe PTSD Damages Children's Brains: Study 2Health News:Severe PTSD Damages Children's Brains: Study 3Health News:Sex After Cancer 2Health News:DVT Treatment Vacuums Away Blood Clots – Prevents Disabilit 2
(Date:9/4/2008)...- Southern Research Institute,today announced that...ted,the organization to participate in the newly-f...Network (MLPCN). The MLPCN -- a collaborative,rese... Program which is,designed to benefit human health... and validate future targets for drug discovery., ...
(Date:9/4/2008)...l activity and favorable safety .../- Idenix,Pharmaceuticals, ... engaged,in the discovery and development of drugs...ious diseases, today announced that it has complet... non-nucleoside reverse,transcriptase inhibitor (N...
(Date:9/3/2008)...ldren Studied. Wrong,Conclusions Reached., NIXA, ...for Disease,Control and Prevention (CDC) study rel...R vaccine and autism. The National Autism Associat...he growing public concern over a,vaccine-autism co...esign,and methodology., For years, parents have c...
(Date:9/3/2008)...sease Awareness Month, CHARLOTTESVILLE, Va., Sept... a clinical-stage drug-development company commerc...cal needs, announced today that it has begun,to en...s lead drug,candidate trans sodium crocetinate (TS...caltrials.gov Website, is investigating TSC as a t...
Breaking Medicine Technology:Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4CDC Misses Target With Flawed MMR/Autism Study 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Heat stress influences low conception of dairy herds 288 1Heat stress influences low conception of dairy herds 288 2Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision 3B Believes Offer Significantly Undervalues Company 666 1Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision 3B Believes Offer Significantly Undervalues Company 666 2Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision 3B Believes Offer Significantly Undervalues Company 666 3Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision 3B Believes Offer Significantly Undervalues Company 666 4Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision 3B Believes Offer Significantly Undervalues Company 666 5Youth Drug Use at a Five Year Low New Survey Shows 662 1Youth Drug Use at a Five Year Low New Survey Shows 662 2Youth Drug Use at a Five Year Low New Survey Shows 662 3Securians Minnesota Life Continues to Climb Group Life Rankings 658 1
...tudy Fails to Meet Primary Endpoint of Improvement... 2007 /PRNewswire-FirstCall/ --,Allos Therapeutics...H, the Company,s pivotal Phase 3 study of Efaproxy...y (WBRT) in women,with brain metastases originatin...its primary endpoint of demonstrating a,statistica...
...SAN DIEGO, June 20, 2007 /PRNewswire-FirstCall/ --...l company committed to,the discovery, development ...reatment of hepatitis and cancer, announced today ...inical development as an,orally-administered direc... C virus (HCV) infection. , "We have identified a ...
Other Medicine Technology:Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 2Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 3Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 4Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 6Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 2Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 3Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 4
Hudson-Downs Burr
McKenzie Perforator Drill
Cushing Perforator Drill
Self retaining brain retractor.
Medicine Products: